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Invasive fungal infections (IFI) constitute a common clinical problem in allogeneic SCT recipients with an incidence of 10-15%. 1, 2 Recent reports suggest that the majority of these infections are caused by Aspergillus sp., [1] [2] [3] [4] but invasive Candida infections are also common in allogeneic SCT recipients. [5] [6] [7] Fluconazole prophylaxis has been widely used in SCT patients due to the results of randomised trials suggesting efficacy. [8] [9] [10] The benefits of the prophylaxis are, however, dependent on the frequency of Candida infections. Moreover, fluconazole prophylaxis is not without potential harms including drug interactions and increasing proportion of infections caused by azole-resistant Candida species. Knowledge of the epidemiological situation of IFI and causative agents is important with regard to rational prophylactic strategies. We have therefore evaluated the epidemiological and clinical features of candidaemia in a large patient cohort who received allogeneic SCT without the use of prophylactic fluconazole.
Patients and methods
In 1983-2002, a total of 685 adult (416 years) patients received an allogeneic SCT at the Department of Medicine, Helsinki University Central Hospital. The main characteristics of the patients and transplant-related issues are summarised in Table 1 .
Transplant protocol
TBI-CY (TBI 12 Gy in six fractions, cyclophosphamide 120 mg/kg) was the standard conditioning regimen throughout the period. A minority of the patients received a conditioning with BU-CY (busulphan 16 mg/kg, cyclophosphamide 120 mg/kg) either in a randomised study protocol, 11 due to previous irradiation, or, in some cases, due to time-scheduling problems for TBI. The patients with aplastic anaemia and related conditions received a conditioning with CY (200 mg/kg) only. A total of 47 patients (7%) received a reduced-intensity conditioning.
GVHD prophylaxis was CyA-Mtx until 1989. In 1989-1993, a randomised study was performed in patients with a matched sibling donor in order to determine whether the addition of methylprednisolone into CyA-Mtx reduces the risk of GVHD. 12 Thereafter, triple prophylaxis became a standard in patients with a sibling donor. All patients with a matched unrelated donor received ATG prior to stem cell infusion. They also received triple prophylaxis until June 1999. Thereafter, methylprednisolone was withdrawn from the combination in order to ameliorate excessive immunosuppression.
Central venous catheters were usually removed at 2 months from SCT if there was no need for prolonged venous access.
Antibacterial prophylaxis
All patients with a matched sibling donor received cotrimoxazole twice a day until recovery from neutropaenia and thereafter twice a day on 3 days per week for prophylaxis against Pneumocystis carinii (PCC). The patients who received the graft from a matched unrelated donor received ciprofloxacin 750 mg twice daily until recovery from neutropaenia and thereafter cotrimoxazole twice a day on 3 days per week for PCC prophylaxis.
Antifungal prophylaxis and empirical therapy
No systemic antifungal prophylaxis was used. From 2000 onwards, patients with acute GVHD treated with high-dose methylprednisolone received daily amphotericin B-inhalations to prevent invasive pulmonary aspergillosis. Intravenous amphotericin B (AmB) was considered in neutropaenic patients if fever persisted for at least 3 days after initiation of broad-spectrum antibiotics. In the case of intolerance to AmB deoxycholate, liposomal AmB was used instead. Altogether, 12% of the patients received empirical AmB (at least for 3 days) during the early post transplant period.
Data collection
All patient charts were carefully reviewed including microbiology files and autopsy data when available to find out patients with IFI. The diagnosis of IFI was based on the identification of fungus from a normally sterile site. This included (a) blood samples taken from peripheral veins; (b) microscopy and culture of needle aspirates or biopsies from normally sterile sites; or (c) identification of IFI by microscopy with or without positive culture at autopsy.
From the patients with candidaemia, the following data was collected: demographics, diagnosis, donor, stem cell source, conditioning regimen, and time to engraftment (neutrophils 40.5 Â 10 9 /l). Also, GVHD and its treatment were recorded as well as the neutrophil count and corticosteroid dose (mg/kg/day) at the time of the diagnosis of candidaemia. Besides the data of the diagnostic studies, the antifungal treatment and the outcome of the patients were recorded as well as the autopsy data when available.
Results

Epidemiology of IFI
During the study period, 60 patients were found to have IFI yielding an incidence of 8.7%. The most common causative organism was Aspergillus sp. (n ¼ 46 patients, incidence 6.7%). Candidaemia was observed only in nine patients (incidence 1.3%); no other cases of invasive Candida infections including patients with hepatosplenic candidiasis were observed. Other fungal infections included Fusarium (n ¼ 2), Absidia (n ¼ 1), Acremonium (n ¼ 1), and Zygomycetes (n ¼ 1).
The incidence of candidaemia showed no significant changes during the study period. There were no cases of candidaemia in 64 patients transplanted in 1983-1987. The incidence of candidaemia was 2.4% (3/125 transplants) in 1988-1992, 0.6% (1/181 transplants) in 1993-1997, and 1.6% (5/315 transplants) in 1998-2002.
Patients with candidaemia
There were six male and three female subjects with a median age of 39 years (range 28-51 years) at the time of SCT. The demographic and major post transplant features of the patients with candidaemia are summarised in Table 2 . The median time to the diagnosis of the fungal infection was 53 days (range 6-249 days) from SCT.
The majority of the patients were neutropaenic at the time of the diagnosis. Two patients had not yet engrafted (day þ 6 and day þ 17 after SCT, respectively). One patient experienced an engraftment failure and received another graft but was found to have candidaemia on day þ 50 from the first graft. Four patients had experienced acute GVHD before the diagnosis. Eight out of nine patients were on corticosteroids at the time of candidaemia. The median dose of methylprednisolone was 0.5 mg/kg/day (0-10).
Candida albicans was the most common causative agent (n ¼ 8), followed by C. krusei (n ¼ 2) and C. glabrata (n ¼ 1). In two patients, two Candida species were concomitantly isolated.
Potential pretransplant risk factors for candidaemia
Owing to the low number of patients with candidaemia, a formal statistical analysis was not considered feasible in this series. The median age of the patients with candidaemia was comparable to the other population (39 vs 41 years). No important differences were observed in the risk of Candida infection with regard to the diagnostic group. Of the major diagnosis (450 transplanted patients), the highest risk was observed in the patients with MDS (2/52, 4%) and the lowest in the patients with CML (1/180, 0.5%). The risk of the candidaemia was 1.2% in the patients who had a matched sibling donor and 1.7% in the patients with an unrelated donor. The type of the graft (BM vs PB) was not predictive of the risk of candidaemia (1.2 vs 1.5%). The risk was also comparable in the patients who received a conventional conditioning regimen when compared to the patients who had received a reduced-intensity conditioning (1.2 vs 2.2%).
Treatment and outcome of candidaemia
All patients received antifungal therapy for a median of 25 days (range 6-108 days). Initially, seven patients were treated with amphotericin B or liposomal AmB, one with miconazole and the most recent patient with caspofungin. The median survival was 24 days from the diagnosis (range 6-280 days). Only one patient was cured of candidaemia. Seven patients subsequently underwent autopsy. The causes of death included GVHD and fungal infection (n ¼ 4), disseminated candidiasis (n ¼ 2), thrombotic thrombocytopenic purpura and candidaemia (n ¼ 1), and post transplantation lymphoproliferative disease (n ¼ 1). The patient who was cured of candidaemia died 9 months after SCT of cerebellar infarct. There were no signs of Candida infection at autopsy.
Discussion
The present retrospective single-centre experience on invasive fungal infections covering a period of two decades showed that the incidence of candidaemia was low throughout the study period. Moreover, infections caused by C. albicans predominated. The fatality rate was high most probably due to severe comorbid conditions, especially GVHD. These observations are of importance with regard to optimal prophylactic and treatment strategies in the setting of allogeneic SCT.
Invasive Candida infections have been regarded as relatively common in SCT recipients with incidence figures ranging from 4.6% 13 to more than 10% in older series. 5, 6 Recently, Safdar et al 7 reported an incidence of Candida infections of 6.8% in allogeneic SCT recipients receiving fluconazole prophylaxis. The incidence of 1.3% for candidaemia in this series is probably the lowest incidence reported in allogeneic SCT recipients. Besides, fluconazole prophylaxis was not used in our patients. Alhough fluconazole prophylaxis may decrease the risk of invasive Candida infections, 9,10 it may not be cost-effective in centres with a low incidence of candidaemia.
Direct comparison of the epidemiological findings of our study with those of other centres is difficult. However, the transplant type (490% received myeloablative conditioning), disease spectrum, and the proportion of the patients receiving grafts from unrelated donors seem to be comparable to many other centres. The low incidence of candidaemia observed in this study may simply reflect the epidemiological situation in our country since Candida infections are rare also in autologous SCT recipients. 14 A minority of our patients received empirical antifungal therapy and perhaps some cases of candidaemia were prevented or effectively treated early but this is clearly not the major explanation for the low incidence figures. It should be noted that considerably higher incidences for candidaemia have been reported from US, 7, 13 where candidaemia is much more common in hospitalised patients when compared to the situation in Finland. 15, 16 In the present series, C. albicans was clearly dominating, probably due to lack of fluconazole prophylaxis. This finding is in a striking contrast with the series reported by Safdar et al 7 where non-albicans strains (C. glabrata, C. krusei, C. parapsilosis) were the causative agents; all patients had received fluconazole prophylaxis. Fluconazole prophylaxis may increase colonisation with azole-resistant Candida species in BMT recipients. 13 Moreover, considering the fact that many cases of candidaemia observed in our Table 2 Characteristics of the patients with candidaemia after allogeneic SCT study were relatively late infections, prophylaxis extending to 75 days post transplant, as in the study of Slavin et al, 9 would have probably been insufficient. The classical risk factors for Candida infections include neutropaenia, GVHD, and steroid use. 17, 18 Although the formal risk factor analysis was not considered feasible in the present study due to the small number of patients with candidaemia, neutropaenia and GVHD were common at the time of the diagnosis of the Candida infection also in this series. No pretransplant factors seemed to be of importance in this regard. Thus, only the development of GVHD with or without prolonged neutropaenia might be a useful hallmark in the prediction of candidaemia in allogeneic SCT recipients. Although these patients undoubtedly have a higher risk for candidaemia, they more commonly have invasive aspergillosis, which makes the use of fluconazole prophylaxis less reasonable. In respect to the epidemiological observations, effective prophylaxis against Aspergillus species would be of paramount importance. A recent randomised study showed that itraconazole was superior to fluconazole in the prevention of IFI in allogeneic SCT recipients, although drug interactions and problems of tolerance limit its use. 19 With regard to its activity against Aspergillus sp., 20 voriconazole might be a useful agent in the prevention of invasive fungal infections in high-risk allogeneic SCT recipients.
Although candidaemia was a rare event in the present series, it was associated with a very poor prognosis. This is in contrast to some studies suggesting a better prognosis in these patients. Martino et al 2 recently reported that only 1/12 of patients who had an invasive Candida infection after allogeneic PBSCT died. Safdar et al 7 reported an overall mortality of 50% and a mortality attributable to fungemia of 21%. The present patients had severe comorbid conditions including GVHD and other severe life-threatening conditions, and many of these patients might not have survived even if the fungal infection could have been effectively treated. In addition to newer drugs such as caspofungin, more effective modes of treatment are needed for these patients possibly including experimental strategies, for example, with dendritic cells pulsed with fungal RNA. 21 To conclude, a low incidence of candidaemia was observed in this single-centre series of allogeneic SCT recipients without the use of systemic antifungal prophylaxis. In these circumstances, fluconazole prophylaxis might not have been cost-effective. Instead, effective prophylaxis against Aspergillus infection seems to be important in allogeneic SCT recipients.
